

Medical Science and Discovery (<http://www.medscidiscovery.com>) is an international open access, peer-reviewed scientific research journal that provides rapid publication of articles in all disciplines of human health, clinical and basic medical science such as Biophysics, Biochemistry, Histology, Physiology, Genetics, Pathology, Toxicology, Anatomical Sciences, Pharmacology, Embryology, Internal and Surgical Medicine.

The policy of top priority of MSD is to put forward and highlight medical innovations and inspiring patents.

MSD offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. The editorial board aims at reviewing the submitted articles as fast as possible and promptly including them in the forthcoming issues.

This journal is published under ethical publishing policy of international scientific Bioethics and publication rules.

MSD supports the Open Access Initiative. Abstracts and full texts (HTML and PDF format) of all articles published by MSD are freely accessible to everyone immediately upon publication.

Medical Science and Discovery has scientific affiliation with **Istanbul University, Cerrahpaşa Medical Faculty** and **Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey**

Indexed Databases: NLM Catalog, Chemical Abstracts (CAS), Index Copernicus, Open Air, ULRICHS Database, Proquest, Advanced Science Index, Turkish Citation Index, Tubitak Ulakbim, Research Bible, Scholar Google

Medical Science and Discovery is an international open access, peer-reviewed scientific research journal. All concession and copyrights belonging to Zafer Akan as Founder

ISSN: 2148-6832 (Print) E-ISSN: 2148-6832 (Online)

Category: Multi Disciplinary Health Science Journal

Abbreviated key title: Med. Sci. Discov.

Frequency: Monthly

Review System: Double Blind Peer Review

Circulation: Globally, Online, Printed

Article Processing Charge (APC): US\$ 100

Licensing: CC-BY-NC 4.0 International License Environmental

Editor-in-Chief: Assoc. Prof. Dr. Arash Khaki

Address: Islamic Azad university ,Tabriz branch ,Dept. of Pathology, Tabriz Iran

Established: 30.04.2014

Web address: www.medscidiscovery.com; <http://dergipark.ulakbim.gov.tr/msd>

E-mail : [editor \[at\] medscidiscovery.com](mailto:editor@medscidiscovery.com)

Phone : +44 020 3289 9294

Design and preparation of PDFs, Language editing, Web site design, Graphical design Services of international Journal of Medical Science and Discovery has been contracted with Lycia Press LONDON, UK (as Publisher), by the MSD Board of Directors

Publisher: Lycia Press Inc.

Address: 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK

Web address: www.lycians.com

Phone : +44 020 3289 9294

E-mail : [office \[at\] lycians.com](mailto:office@lycians.com)

E-mail : [info \[at\] lycians.com](mailto:info@lycians.com)

Editorial Board of Medical Science and Discovery

Honorary Editors

Prof. Dr.	Aziz Sancar	University of North Caroline, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA
Prof. Dr.	Giancarlo BAROLAT	Barolat Institute, 1721 E 19th Ave #434, Denver, CO 80218, USA
Prof. Dr.	Joyce REARDON	University of North Caroline, Dept. of Biochemistry-Biophysics, Chapel Hill, NC, USA
Prof. Dr.	Metin TULGAR	Yuzuncu Yil University, School of Medicine, Dept. of Biophysics, Van, TR

Deputy Editors

Assoc. Prof.	Michael George KEMP	University of North Carolina, 120 Mason Farm Road, Campus Box 7260, Genetic Medicine Bldg Room 3010 Chapel Hill, NC 27599 USA
Assoc. Prof.	Zafer Akan (Founder)	Lycia Press Inc., 3rd Floor 86 - 90 Paul Street, EC2A 4NE, London, UK

Internal Medicine

Asist. Prof. Dr.	Adnan ÇOBAN	Halic University, Faculty of Medicine Dept. of Psychiatry, Istanbul
Asist. Prof. Dr.	Ahmet ÇİNKAYA	CBU, Faculty of Medicine, Dept. of Radiation Oncology
Asist. Prof. Dr.	Ahmet YILMAZ	Dicle University, Faculty of Medicine, Dept. of Family Medicine
Prof. Dr.	Ali Rıza Bilge	CBU, Faculty of Medicine, Dept. of cardiology, Manisa, TR
Assoc. Prof. Dr.	Alparslan ŞAHİN	Dicle University, Faculty of Medicine, Dept. of Eye
Prof. Dr.	Ayşe YÜKSEL	Yuzuncu Yil University, Faculty of Medicine, Dept. of Public Health, Van
Assoc. Prof. Dr.	Bekir Serhat YILDIZ	PAU, Faculty of Medicine, Dept. of Cardiology, Denizli, Turkey
Asist. Prof. Dr.	Gökmen BILGILI	CBU, Faculty of Medicine, Dept. of Neonatology, Manisa, TR
Prof. Dr.	Hatice Sınav USLU	ISMU, Faculty of Medicine, Dept. of Nucleer Medicine, Istanbul, TR
Prof. Dr.	Hikmet YILMAZ	CBU, Faculty of Medicine, Dept. of Neurology, Manisa, TR
Assoc. Prof. Dr.	Hasan GUNGOR	Adnan Menderes University, Faculty of Medicine Dept. of Cardiology, Aydin, TR
Assoc. Prof. Dr.	Huseyin GUDUCUOGLU	YYU Faculty of Medicine, Dept. of Microbiology, Van
Asist. Prof. Dr.	Murat ÖZSARAÇ	CBU, Faculty of Medicine, Dept. of Emergency Medicine
Prof. Dr.	Muzaffer POLAT	CBU, Faculty of Medicine, Dept. of Pediatric Neurology
Assist. Prof. Dr.	Nesrin CEYLAN	Ankara Children's Health, Training and Research Hospital, Department of Hematology Oncology , Ankara, Turkey
Prof. Dr.	Nobuo INOTSUME	Hokkaido Pharmaceutical University, Clinical Pharmacology, Hokkaido AC, JAPAN
Assist Prof. Dr.	Secil ILHAN YILMAZ	Erciyes University, Genom and Stem Cell Research Center, Kayseri, TR
Prof. Dr.	Talat ECEMIS	CBU, Faculty of Medicine, Dept. of Microbiology, Manisa, TR
Asist. Prof. Dr.	Tarık ULUCAY	CBU, Faculty of Medicine, Dept. of Forensic Medicine
Assist Prof. Dr.	Younes El Bouzekri EL IDRISSI	Place Aboubakr, Imm 22, App 6, Bd Fal ould oumeir, Agdal Rabat
Assist Prof. Dr.	Yusuf Kemal DEMIR	Marmara University, Faculty of Pharmacy, Dept. of Pharmaceutical Tech. Istanbul TR

Editorial Board of Medical Science and Discovery

Surgical Medicine

Assoc. Prof. Dr. Mustafa USLU	Duzce University, Faculty of Medicine, Dept. of Orthopedics, Bolu
Assoc. Prof. Dr. Abdullah BOYUK	Dicle University, Faculty of Medicine, Dept. of General Surgery
Assist. Prof. Dr. Christopher Schmitt	University of California, San Francisco Cardiovascular Res. Inst.
Prof. Dr. Çetin DİNÇEL	Hacettepe University, Faculty of Medicine, Dept. of Urology
Prof. Dr. Cuneyt Temiz	CBU, Faculty of Medicine, Dept. of Neurosurgery, Manisa
Prof. Dr. Gönül Tezcan KELEŞ	CBU, Faculty of Medicine, Dept. of Anesthesiology and Rean.
Prof. Dr. M. Derya BALBAY	Memorial Hospital, Dept. of Urooncology
Asist. Prof. Dr. Murat YILDIR	BAU Faculty of Medicine, Dept. of General Surgery
Prof. Dr. Nasuhi Engin AYDIN	Katip Çelebi University, Faculty of Medicine, Dept. of Pathology
Assist. Prof. Dr. Pinar SOLMAZ HASDEMİR	CBU, Faculty of Medicine, Dept. of Obstetrics and Gynecology, Manisa
Assoc. Prof. Dr. Tevfik GUNES	PAU, Faculty of Medicine, Dept. of Cardiovascular Surgery, Denizli,
Assoc. Prof. Dr. Yusuf Izzettin ALIHANOGLU	PAU, Faculty of Medicine, Dept. of Cardiology, Denizli

Basic Sciences

Prof. Dr. Arash KHAKI	Islamic Azad university ,Tabriz branch ,Dept. of Pathology, Tabriz Iran
Dr. Alper Tunga ÖZDEMİR	Manisa ME State Hospital Dept. of Medical Biochemistry
Assoc. Prof. Dr. Anzel BAHADIR	Duzce University, Faculty of Medicine, Dept. of Biophysics, Bolu, TR
Assoc. Prof. Dr. Ayse Inhan GARIP	Marmara University, Faculty of Medicine, Dept. of Biophysics
Assoc. Prof. Dr. Bahriye ŞİRAV	Gazi University, Faculty of Medicine, Dept. of Biophysics
Prof. Dr. Beki KAN	Acıbadem University, Faculty of Medicine, Dept. of Biophysics
Prof. Dr. Cevval ULMAN	CBU, Faculty of Medicine, Dept. of Biochemistry, Manisa, TR
Assoc. Prof. Dr. Gokhan OTO	YYU Faculty of Medicine, Dept. of Pharmacology, Van, TR
Prof. Dr. Halit DEMİR	YYU Faculty of Science, Dept. of Biochemistry
Prof. Dr. Hasan YILMAZ	YYU Faculty of Science, Dept. of Parasitology, Van, TR
Prof. Dr. M. Ali KORPINAR	Istanbul University, Cerrahpasa Medical Faculty, Dept. of Biophysics, Istanbul
Dr. Muhammed B. BATIR	CBU, Faculty of Medicine, Dept. of Genetic, Manisa, TR
Prof. Dr. Mustafa ÖZBEK	CBU, Faculty of Medicine, Dept. of Physiology
Asist. Prof. Dr. Mujdat AYTEKİN	Haliç University, Faculty of Medicine, Dept. of Clinical Biochemistry, Istanbul
Dr. Ömer KACAR	TUBITAK MAM Dept. of Molecular Biology, Gebze, TR
Asist. Prof. Dr. Özdemirhan Serçin	Interdisciplinary Research Institute, Université Libre de Bruxelles, Belgium
Prof. Dr. Seda VATANSEVER	CBU, Faculty of Medicine, Dept. of Histology and Embryology
Prof. Dr. Sevinç İNAN	CBU, Faculty of Medicine, Dept. of Histology and Embryology
Asist. Prof. Dr. Shoban GADDAMADI	Washington State University College of Pharmacy, Dept. of Experimental and Systems Pharmacology, Spokane, WA, USA
Assoc. Prof. Dr. Tamer ZEREN	CBU, Faculty of Medicine, Dept. of Biophysics
Prof. Dr. Tunaya KALKAN	Istanbul University, Cerrahpasa Medical Faculty, Dept. of Biophysics, Istanbul

Statistical Editor

Prof. Dr. Sıddık KESKİN	YYU Faculty of Medicine, Dept. of Medical Statistics
-------------------------	--

Language Editor

Asist. Prof. Dr. Hakan ERGİN	Istanbul University, Dept. of Foreign Languages
------------------------------	---

Editorial Office


Typist	Office Lycia Press	office@lycians.com
Web	Web Lycia Press	info@lycians.com

Instruction for Authors

- **Important**
- MSD is committed to deterring plagiarism, including self-plagiarism. Your manuscript will screen to compare for similarity with published articles.
- For research studies using human or animal subjects, the trial's design, conduct and reporting of results must conform to Good Clinical Practice guidelines (such as the Good Clinical Practice in Food and Drug Administration (FDA)-Regulated Clinical Trials (USA) or the Medical Research Council Guidelines for Good Clinical Practice in Clinical Trials (UK)) and/or to the World Medical Association (WMA) Declaration of Helsinki
- Dear Authors, please upload just these three files to the manuscript submission system
- [Title Page Sample](#)
- [Manuscript Sample](#)
- [Copyright Transfer and Author Consent Form](#)
- Please select Keywords from the MESH source
- (<https://www.nlm.nih.gov/mesh/MBrowser.html>)
- Manuscripts should be prepared in accordance with the "Uniform Requirements for Manuscripts Submission to Biomedical Journals" proclaimed by the International Committee of Medical Journal Editors (www.icmje.org).
- MSD uses vancouver reference style, please prepare articles due to Vancouver reference style rules.
-
- **Manuscript Preparation Rules**
- **1. Cover letter**
- **a-** A statement that the manuscript has been read and approved by all the authors.
- **b-** That the requirements for authorship have been met for all the authors, based on the criteria stated by *ICMJE*.
- **c-** Approval of all the authors regarding the order in which their names have appeared.
- **d-** That each author confirms the manuscript represents honest work.
- **e-** The name, address, and telephone number of the corresponding author who is responsible for communicating with other authors about revisions and final approval.
- **f-** The letter should give any additional information that may be helpful to the editor, such as the type or format of the article. If the manuscript has been submitted previously to another journal or in another language, it is helpful to include the previous editor's and reviewers' comments with the submitted manuscript, along with the authors' responses to those comments. Submitting previous evaluatory review of another journal accelerates the review process.
- **g-** For accepted manuscripts, the authors are requested to fill and sign the journal's cover letter to express their consent for its publication.
- **h-** To reproduce published material, to use illustrations or tables or report information about identifiable people, the author should submit a copy of the permission with the manuscript to the journal.
- **2. Top Ethic Committee Approval**
Inclusion of the approval letter from the relevant Ethics Committee or Institution's Review Board regarding the research protocol and the rights of the subjects (if applicable to the study)
- **3. Top Consent Form**
Attach a copy of the consent form to the letter, if applicable. Consent forms would be evaluated by the Ethics Committee and then signed by the participant.
- **4. Top RCT or NCT Registration**
Emailing the letter denoting registration of RCTs or NCTs in domestic or international databases (The trial's registration number needs to be mentioned, too).
- 5. Manuscripts submitted in English, must be type written, double-spaced, on good quality A4 paper, or paper of similar format. Authors are requested to reserve margins of at least 2.5cm all around the paper. Original drawings of photos, tables and figures should be furnished together with the manuscripts.
- 6. Manuscripts should be kept to a minimum length and should be subdivided into labeled sections (Title page, Abstract, Keywords, Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement, and References).
- 7. A title page is to be provided and should include the title of the article, authors' names with full first name (with degrees), authors' affiliation, suggested running title and corresponding author. The affiliation should comprise the department, institution (usually university or company), city and state (or nation). The suggested running title should be less than 50 characters (including spaces) and should comprise the article title or an abbreviated version thereof. For office purposes, the title page should include the name and complete mailing address, telephone and fax number, and email of the one author designated to review proofs.
- 8. An abstract no longer than 250 words for reviews and research articles is to be provided as the second page. Abstract should be structured as objective(s) (including purpose setting), materials and methods, results, and conclusion.

Instruction for Authors

- **Case Report**
- A case report is a case study, case report, or other description of a case that should contain 1500 - 2000 words with a structured abstract of 200 words maximum. Case reports should comprise sections of Introduction, Case Presentation, and Conclusions in Abstract and Introduction, Case Presentation, and Discussion in full text with not more than 2 tables or figures and up to 20 references.
- **Brief Report**
- Brief Reports should contain 1000 - 2000 words with a structured abstract of 200 words maximum. Short reports should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Short Communication**
- Short Communication, follow the instructions for original articles, except that the total word number of the main text (excluding references, tables and figure legends) is limited to 2000 with no more than 2 figures and/or tables and no more than 15 references. An abstract, not exceeding 150 words, should be presented at the beginning of the article.
- **News**
- News should contain 1000 - 2000 words with a structured abstract of 200 words maximum. News should comprise sections of Background, Objectives, Materials & Methods, Results and Discussion with not more than 2 tables or figures and up to 20 references.
- **Publication Policies**
- Manuscripts, or the essence of their content, must be previously unpublished and should not be under simultaneous consideration by another Journal. The authors should also declare if any similar work has been submitted to or published by another Journal. By virtue of the submitted manuscript, the corresponding author acknowledges that all the co-authors have seen and approved the final version of the manuscript. The corresponding author should provide all co-authors with information regarding the manuscript, and obtain their approval before submitting any revisions. Manuscripts are only accepted for publication on the understanding that the authors will permit editorial amendments, though proofs will always be submitted to the corresponding author before being sent finally to press. Prior to the initial submission of a new manuscript, please carefully consider that all authors' names are included as no change to authors' details will be permitted after the acceptance. The decision to accept a contribution rests with the Editorial Board of the MSD.
- Manuscripts will be considered for publication in the form of original articles, Case report, short communications, Letter to editor and review articles. The work should be original or a thorough by an authoritative person in a pertinent field.
- **Peer review process**
- All submissions will be reviewed anonymously by at least two independent referees. All manuscripts will be acknowledged upon presenting to the Journal office, provided that all stated requirements are met. Authors are encouraged to suggest names of three expert reviewers, but selection remains a prerogative of the Editor. The whole review process depends on receiving referees comments and revising the manuscripts based on these comments to the author. On receipt of the revised article from the author, and after final approving by referees, the letter of acceptance is issued to the author. Authors have the right to communicate to the editor if they do not wish their manuscript to be reviewed by a particular reviewer because of potential conflicts of interest. No article is rejected unless negative comments are received from at least two reviewers. **MSD employs double blind reviewing process, where both the referee and author remain anonymous throughout the process.**



Instruction for Authors

- **Ethical Rules and Rights**
- **Conflicts of interest**
- Conflicts of interest arise when authors, reviewers, or editors have interests that are not fully apparent and that may influence their judgments on what is published. They have been described as those which, when revealed later, would make a reasonable reader feel misled or deceived. (The Committee on Publication Ethics (COPE) states in its Guidelines on Good Publication Practice 2003).
- Authors should disclose, at the time of submission, information on financial conflicts of interest or other interests that may influence the manuscript. Authors should declare sources of funding for the work undertaken.
- **The Journal's Policy on Plagiarism**
- Any practice of plagiarism will not be tolerated by the journal regarding submitted manuscripts. Non-identifiable quoted segments of articles or close paraphrases from other author/s or even submitting the author's previously published work are known as the act of plagiarism by this journal unless proper use of quotations or paraphrasing with decent citation or referencing are in place. Heavy use of one or a couple of articles is discouraged, even if paraphrased fully. Adherent practice of plagiarism will abort reviewing process or later submission to this journal. All submitted articles will evaluate by *iThenticate* software belonged to cross check for stop any plagiarism and improve publication quality.
- **Statement of Human and Animal Rights**
- All submitted articles involving human experiments should be performed only in accordance with the ethical standards provided by the responsible committee of the institution and in accordance with the Declaration of Helsinki (as revised in Edinburgh 2000), available at <http://www.wma.net/en/30publications/10policies/b3/index.html>. Papers describing animal experiments can be accepted for publication only if the experiment conforms the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978) for the care and use of Laboratory Animals for experimental procedure. Authors must provide a full description of their anesthetics and surgical procedures. All manuscripts reporting the results of experimental investigations involving human subjects should include a statement confirming the informed consent was obtained from each subject or subject's guardian.
- **Humans:** When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
- **Animals:** When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
- All animal or human subjects should be used after approval of the experimental protocol by a local ethics committee.
- **Acknowledgements**
- Contributors: In acknowledgement section, name people for their contributions or their permission to reproduce their published material, to use their illustrations or provide information about them- try to fully name people who have helped from the conception of the idea to adoption of the hypothesis, to finalization of the study, etc., earnestly. Statement of financial support: Aside from the title page, state any financial or other relationships that might lead to a conflict of interest.
- **Copyright**
- After acceptance and publication; all ownership rights and Copyrights of the manuscript, passes to international journal of Medical Science and Discovery. Please complete copyright form and send via email to editor. [Download MSD Copyright Transfer and Author Consent Form](#)
- This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](#).
- Copyright © 2014: The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. All Rights reserved by international journal of Medical Science and Discovery.
- **Disposal of material**
- Once published, all draft copies of the manuscript, correspondence and artwork will be held at least for 6 months before disposal. Authors and Readers may find original PDF file of article on backup servers such as CLOKKS (<https://www.clockss.org/>)
- **Digital Object Identifier DOI**
- Once a manuscript is accepted for publication it will be provided with a registered DOI number following the acceptance decision. Manuscripts accepted for publication by the **MSD** will be published as ahead of print articles prior to the printing date of their scheduled issue. Corresponding author will be provided with a PDF Proof by the publisher once the production process of an accepted manuscript is over.

Instruction for Authors

- **Article Processing Charge**
- MSD is a non-profit Scientific Journal Platform; however, it uses professional services such as Language Editing, DOI, domain and hosting, iThenticate Plagiarism or similarity detection Detection Software. All of these professional services are used for all the article processes and an inevitable cost arises with this.
- Unfortunately, like most open journals, fees of the publication with MSD are charged to Authors. Payment is under the responsibilities of corresponding Author(s). MSD does not charge any fee during the submission period. However, after the peer-review process, a non-refundable charge (100 USD) for each accepted manuscript must be paid by the author(s) via MSD's official PayPal account. An invoice will be sent for each accepted manuscript to corresponding author(s).
- **Following with completion of payment procedure, the galey proof and acceptance letter of article will be send to authors for last check**
- Preperation of articles in PDF and HTMLformat is covered by Lycia Press Inc. (press.lycians.com) and Article Processing Charges paid to Lycia Press Inc. (press.lycians.com)
- **MSD revenue sources and Sponsorships**
- All costs arising from the publications are covered by the Sponsor Companies and Article Processing Charges. Sponsorship request evaluates by the MSD Journal Management Board and the **sponsor company logos** will be included on the back page of printed magazine and in the sponsor section of journal website

	Article Processing Charge (APC)	Discount %
Regular	100 USD	
for Editorial Board Members	70 USD	30%
for Afiliated Institution Members	80 USD	20%

- *APC not includes Proofreading Services fee. Editor in Chief may direct the corresponding Author to Lycia Press, Language Office for Proofreading Service lycians.com
-
- **References**
- Committee on Publication Ethics (COPE). (2011, March 7). Code of Conduct and Best-Practice Guidelines for Journal Editors. Retrieved from http://publicationethics.org/files/Code_of_conduct_for_journal_editors_Mar11.pdf
- World Association of Medical Editors (WAME). Principles of Transparency and Best Practice in Scholarly Publishing. <http://www.wame.org/about/principles-of-transparency-and-best-practice>

Contents

Case Reports

Thyrotoxicosis due to functioning metastatic follicular thyroid cancer

Sadiye Altun Tuzcu, Faruk Kilinc, Zafer Pekkoy, Hikmet Soylu, Alpaslan Kemal Tuzcu

339-41

Thyrotoxicosis formation due to functioning metastatic follicular thyroid cancer

Sadiye Altun Tuzcu^{1*}, Faruk Kılınç², Zafer Pekkolay³, Hikmet Soylu³, Alpaslan Kemal Tuzcu³

Abstract

Thyrotoxicosis is a common condition, which is associated with excess circulating thyroid hormones. Rarely, thyrotoxicosis may develop due to metastatic thyroid carcinoma. Most of patients with functional thyroid cancer metastases have normal thyroxine (T4) concentrations with high serum triiodothyronine (T3-thyrotoxicosis). Inappropriately suppressed Thyroid Stimulating Hormone (TSH) level with normal T4 level may be an indicator of T3 thyrotoxicosis. In this article, a thyrotoxicosis case, due to metastatic follicular thyroid cancer with a huge metastatic lesion was represented.

Keywords: Adenocarcinoma, Follicular, Thyrotoxicosis

Introduction

Thyrotoxicosis is a common condition associated with excess circulating thyroid hormones. It is important to identify the cause of the thyrotoxicosis to determine treatment approaches. Graves' disease, toxic multinodular goitre, thyroid nodule, thyroiditis, drugs (such as amiodarone, lithium, interferon α), β human chorionic gonadotrophin mediated hyperthyroidism (gestational hyperthyroidism, choriocarcinoma, hydatidiform mole) Struma ovary, non-autoimmune familial hyperthyroidism and Thyroid Stimulating Hormone (TSH) secreting pituitary adenoma are the important causes of thyrotoxicosis (1). Rarely, thyrotoxicosis may develop due to functioning of metastatic thyroid carcinoma (2, 3). In this case report we present a recognised case of thyrotoxicosis due to metastatic follicular thyroid cancer with a huge metastatic lesion.

Case Report

A 59-year-old female patient was admitted to our clinic with a painful, progressively enlarging mass around her right shoulder. The patient had elevated serum free triiodothyronine (free T3) normal serum free thyroxine (free T4) and low thyroid-stimulating hormone (TSH) Blood hormone levels of patient were shown in Table 1. The patient had thyroidectomy history 10 years ago due to multinodular goitre. She had not informed about her thyroid pathology. She had noticed a growing mass on the right shoulder for few years.

Three years ago, biopsy of the mass had been performed and pathological examination revealed the thyroid follicular cancer. The patient had not taken any medication. Moreover, the physical examination revealed that the patient has a right scapular mass. In addition, patient also has diabetes and getting intensive insulin therapy. Complete blood count was normal. The patient's elevated alkaline phosphatase and residual thyroid tissue (19X11mm) could be observed at the right side of the neck by ultrasonographic examination. The whole body was scanned using radioiodine imaging with I-131. The results showed an increased uptake in right scapular infero-lateral region (Figure 1). The MRI scan of the right shoulder showed a huge mass (150X111 mm), which includes bone and soft tissue (Figure-2a/2b). We planned metastatic mass excision, followed by the radioiodine ablation treatment, but the patient did not accept our therapy recommendations.

Table 1: Laboratory characteristics of the patient

	Normal range	Patient's result
TSH (uIU/ml)	0.270-4.2	0,01
Free T4 (ng/dL)	12-22	3.91
Free T3 (ng/dL)	3,9-6,7	18,57
Tiroglobulin (ng/mL)	1,4-78	500
Alkaline phosphatase (U/L)	40-150	259
Glucose (mg/dL)	70-109	196

Received 29-09-2016 Accepted 11-10-2016 Available Online 15-10-2016

1 Gazi Yasargil Education and Research Hospital, Dept of Nuclear Medicine, Yenisehir, Diyarbakir, Turkey,

2 Elazig Education and Research Hospital Dept of Endocrinology, Elazig, Turkey,

3 Dicle University Faculty of Medicine Dept of Endocrinology Diyarbakir, Turkey

* Corresponding Author: Sadiye Altun Tuzcu E-mail: sadiyetuzcu@yahoo.com.tr Phone: +90 412 258 0060






Figure 1: Whole body radioiodine imaging with I-131 showed increased uptake in the right scapular region




Figure 2a Magnetic Resonance Imaging (MRI) of the patient's right shoulder (Upward-Over)




Figure 2b Magnetic Resonance Imaging (MRI) of the patient's right shoulder (Front)

Discussion

The formation of thyrotoxicosis due to functional thyroid cancer metastases is extremely rare, and is mostly caused by follicular cancer. Even so, hyper functioning papillary thyroid cancer has been documented (3,4). The patient had follicular cancer of the thyroid gland.

The functional metastases had been identified using whole body radioiodine imaging. of the patient with I-131. The results have shown an increased uptake in right scapular region. Previously, she was not informed or aware about her pathology specimen and was not treated with high dose radioactive iodine for thyroid cancer ablation. Small metastasis of follicular cancer of the thyroid may be asymptomatic, but bulky and extensive metastasis of cancer may lead to thyrotoxicosis.

The majority of patients with functional thyroid cancer metastases have had high serum triiodothyronine (T3) but normal thyroxine (T4) concentrations (T3-thyrotoxicosis). Patients who have thyrotoxicosis due to functioning metastatic thyroid carcinoma have predominantly T3 thyrotoxicosis (2).

Our patient's serum thyroglobulin and free T3 were elevated. She had normal free t4 and suppressed TSH level. Thyroid cancer patients especially follow up with thyroglobulin, free t4 and TSH levels but, in our opinion at least once a year, measuring free t3 may be helpful and give an opportunity to diagnose T3 thyrotoxicosis cases.

In patients who take TSH-suppressive thyroid hormone therapy with L-thyroxine after total thyroidectomy, the presence of hyper functioning metastases may not be readily occur. Gradual reduction or withdrawal of L-thyroxine therapy is necessary in order to recognize whether the thyrotoxicosis is caused by excessive exogenous levothyroxine or hyper functioning metastases. The mechanism is high activity of the type 1 and type 2 iodothyronine deiodinases in tumour tissues, ie. exogenously administered levothyroxine is converted to T3 (5).

A few of these patients have also had serum TSH-receptor stimulating antibodies, the presence of which would be expected to increase the hormonal synthetic capacity of the cancer (6). We did not measure TSH -receptor stimulating antibodies level due to technical failure.

Conclusion

In conclusion, 1- Follicular thyroid cancer can cause hyper functioning metastatic huge mass lesions. 2- Inappropriately suppressed TSH levels with normal T4 levels may be helpful to suspect T3 thyrotoxicosis.

Conflict of Interest: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgement: Author Contributions: A.K.T.: Concept, S.A.T.: Design, Z.P.: Data collection and processing, F.K.: Literature search, H.S.: Writing

Ethical issues: All Authors declare that Originality of research/article etc... and ethical approval of research, and responsibilities of research against local ethics commission are under the Authors responsibilities. The study was conducted due to defined rules by the Local Ethics Commission guidelines and audits.

References

1. Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. *BMJ*. 2014 Aug 21;349:g5128.
2. Nakashima T, Inoue K, Shiro-ozu A, Yoshinari M, Okamura K, Itoh M. Predominant T₃ synthesis in the metastatic thyroid carcinoma in a patient with T₃-toxicosis. *Metabolism*. 1981 Apr 30;30(4):327-30.
3. Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. *Endocrinology and metabolism clinics of North America*. 1990 Sep;19(3):593-612.
4. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S, Belfiore A. Detection of an Activating Mutation of the Thyrotropin Receptor in a Case of an Autonomously Hyperfunctioning Thyroid Insular Carcinoma 1. *The Journal of Clinical Endocrinology & Metabolism*. 1997 Mar 1;82(3):735-8.
5. Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E, Nishikawa M. 3, 5, 3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. *The Journal of Clinical Endocrinology & Metabolism*. 2008 Jun;93(6):2239-42.
6. Kasagi K, Takeuchi R, Miyamoto S, et al. Rapid Control of T₃ Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. *Clin Endocrinol (Oxf)* 1994; 40:429.



MEDICAL SCIENCE & DISCOVERY



ISSN: 2148-6832

Lycia Press LONDON UK



International Journal of
Medical Science and Discovery
Open Access Scientific Journal
October 2016, Vol.3, No.10

www.medscidiscovery.com